BIRC3 Antibody / Baculoviral IAP repeat-containing protein 2 / cIAP2, 100ul

BIRC2 antibody targets Baculoviral IAP repeat-containing protein 2 (BIRC2), also known as cellular inhibitor of apoptosis 1 (cIAP1), a ubiquitin-binding regulatory protein that plays a central role in controlling cell survival and inflammatory signaling. BIRC2 is a member of the inhibitor of apoptosis protein family. In the cytoplasm, it associates with receptor-proximal signaling complexes. The protein contains multiple baculoviral IAP repeat domains that mediate protein interactions, along with a C-terminal RING finger domain that confers E3 ubiquitin ligase activity. These structural features allow BIRC2 to act as a signaling modulator rather than a direct enzymatic inhibitor of caspases.<br><br>Functionally, BIRC2 is best characterized for its role in tumor necrosis factor receptor signaling pathways. Upon receptor activation, BIRC2 promotes ubiquitination of key adaptor proteins, facilitating assembly of signaling complexes that activate NF-kappaB and related pro-survival pathways. Through this mechanism, BIRC2 suppresses apoptotic and necroptotic signaling while supporting transcriptional programs involved in inflammation and immune regulation. BIRC2 therefore acts as a molecular checkpoint that determines whether cells undergo survival or death in response to external stimuli. A BIRC2 antibody supports studies examining how ubiquitin-mediated signaling influences these outcomes.<br><br>BIRC2 expression is broadly distributed across tissues and cell types, reflecting its fundamental role in regulating survival signaling. Its abundance and activity can be dynamically regulated by cytokine exposure, cellular stress, and interaction with other IAP family members. BIRC2 can also undergo auto-ubiquitination and proteasomal degradation, providing a feedback mechanism to fine-tune signaling duration. Analysis of BIRC2 localization and expression offers insight into how cells adapt survival pathways under changing physiological conditions.<br><br>From a biological and disease-relevance perspective, BIRC2 has been widely studied in cancer biology and immunology. Elevated or stabilized BIRC2 expression has been observed in multiple tumor types, where it can contribute to resistance to cell death and altered inflammatory signaling. BIRC2 is also involved in immune and inflammatory responses, making it relevant to studies of chronic inflammation and immune-mediated disease. Because of its central role in coordinating ubiquitin-dependent signaling, BIRC2 remains an important research focus in investigations of therapeutic resistance and signaling pathway modulation.<br><br>At the molecular level, BIRC2 is encoded by the BIRC2 gene and produces a protein of approximately 68 kDa. The baculoviral IAP repeat domains enable interaction with signaling proteins, while the RING finger domain directs ubiquitin chain assembly that shapes downstream signaling. Proper BIRC2 function depends on its integration into multiprotein complexes and regulated ubiquitin ligase activity. A BIRC2 antibody supports research applications focused on apoptosis regulation, ubiquitin signaling, and inflammatory pathway analysis, with NSJ Bioreagents providing reagents intended for research use.

Specifications